menu
    • menu
    [{"orgOrder":0,"company":"Noventia Pharma","sponsor":"Delbert Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Histamine Dihydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Noventia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Noventia Pharma \/ Delbert Lab","highestDevelopmentStatusID":"12","companyTruncated":"Noventia Pharma \/ Delbert Lab"}]

    Find Clinical Drug Pipeline Developments & Deals for Histamine dihydrochloride, United States Pharmacopeia (USP) Reference Standard

    Menu

    Histamine dihydrochloride, United States Pharmacopeia (USP) Reference Standard

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Noventia Pharma

                            Italy arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Noventia Pharma

                            Italy arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            DELBERT Laboratories Are Proud to Announce the Acquisition From Noventia Pharma Srl of the European Marketing ...

                            Details : Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.

                            Brand Name : Ceplene

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth